<DOC>
	<DOCNO>NCT00456248</DOCNO>
	<brief_summary>This 60-to-72 week multicenter study evaluate Infergen Ribavirin patient Chronic Hepatitis C Virus partial response treatment use peginterferon-alfa Ribavirin therapy . The study conduct approximately 50 site across United States .</brief_summary>
	<brief_title>Infergen Ribavirin Treatment Patients With HCV Who Achieved Partial Response Peginterferon-alfa Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon alfacon-1</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female , least 18 year age old 65 year compensate chronic HCV infection base history positive serum antiHCV antibody and/or HCV RNA Diagnosed HCV Genotype 1 , 4 , 5 6 determine screen visit The starting dose initial treatment must 1.5 μg/kg/week PEGIntron 180 μg/week Pegasys , 1000/1200 mg/day ribavirin base body weight . Patients must least 80 % compliant initial peginterferon/ribavirin therapy , per patient account . Liver biopsy indicate F0F4 must perform within 3 year prior screen . Documentation result biopsy must available . If documentation available , liver biopsy must perform screening period . ( A maximum 10 patient three treatment group patient fibrosis score F4 ) Documented partial response 12 week treatment therapynaive patient one course peginterferon alfa2a ( PEGASYS ) Ribavirin peginterferon alfa2b ( PegINTRON ) Ribavirin Detectable HCV RNA 12 week initial peginterferon alfa/ribavirin therapy &lt; 2 log decrease HCV RNA Week 12 baseline . HCV Genotype 2 3 Severe neuropsychiatric disorder . History clinical manifestation significant metabolic , hematological , pulmonary , ischemic heart disease , significant unstable heart disease , gastrointestinal , neurological , renal , urological , endocrine , ophthalmologic disorder include severe retinopathy , immunemediated disease . Known HIV infection positive HIV screening . Pregnant breastfeeding patient . Underlying autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Liver</keyword>
	<keyword>Pegylated</keyword>
	<keyword>Interferon</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Combination</keyword>
	<keyword>Nonresponder</keyword>
	<keyword>Relapser</keyword>
	<keyword>HCV</keyword>
	<keyword>Infergen</keyword>
	<keyword>SVR</keyword>
</DOC>